Crystal Adam 4

What Happened
Crystal Adam, President of R&D at Tango Therapeutics (TNGX), exercised 27,000 option shares (exercise price $5.20) on 2026-04-01 for a cash cost of $140,400 and sold the 27,000 shares in open-market transactions the same day for total proceeds of $572,478. The filing also shows the related derivative (the option) was canceled/converted upon exercise (reported as a $0.00 disposition). The transactions were executed under a pre-established Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-04-01; Form 4 filed 2026-04-02 (appears timely).
• Exercise: 27,000 shares at $5.20 — total exercise cost $140,400. (Code M)
• Sale: 27,000 shares sold in open market at a weighted-average price $21.20 — total proceeds $572,478. (Code S)
• Derivative disposition: 27,000 shown at $0.00 reflecting the option conversion/cancellation. (Code M)
• Footnotes: F1 — trades effected under a 10b5-1 plan adopted 2025-10-27; F2 — sale price is a weighted average (prices ranged $21.00–$21.69); F3 — option vesting schedule described in filing.
• Shares owned after transaction: not specified in the supplied excerpt of this filing — check the full Form 4 for updated ownership.

Context
Because the shares were exercised and sold the same day, this is effectively a cashless exercise (exercise followed by immediate sale). The 10b5-1 plan note indicates these trades were pre-planned, which is common for scheduled insider sales and does not, by itself, signal non-public information. For a complete picture of insider ownership and any tax-withholding or net-share settlement, review the full Form 4 filing.